Raymond James Trust N.a. buys $14,739,841 stake in Pfizer (PFE)

Pfizer (PFE) : Raymond James Trust N.a. scooped up 1,709 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 20, 2016. The investment management firm now holds a total of 443,037 shares of Pfizer which is valued at $14,739,841.Pfizer makes up approximately 1.30% of Raymond James Trust N.a.’s portfolio.

Pfizer opened for trading at $33.25 and hit $33.5 on the upside on Friday, eventually ending the session at $33.27, with a gain of 0.09% or 0.03 points. The heightened volatility saw the trading volume jump to 2,61,37,321 shares. Company has a market cap of $205,746 M.

Other Hedge Funds, Including , Windsor Financial Group boosted its stake in PFE in the latest quarter, The investment management firm added 8,272 additional shares and now holds a total of 133,284 shares of Pfizer which is valued at $4,434,359. Pfizer makes up approx 2.00% of Windsor Financial Group’s portfolio.Amarillo National Bank reduced its stake in PFE by selling 1,559 shares or 12.23% in the most recent quarter. The Hedge Fund company now holds 11,192 shares of PFE which is valued at $363,740. Pfizer makes up approx 0.26% of Amarillo National Bank’s portfolio.Newman Dignan Sheerar boosted its stake in PFE in the latest quarter, The investment management firm added 16,087 additional shares and now holds a total of 31,283 shares of Pfizer which is valued at $1,016,698. Pfizer makes up approx 0.73% of Newman Dignan Sheerar’s portfolio.Community Trust Investment Co boosted its stake in PFE in the latest quarter, The investment management firm added 85,476 additional shares and now holds a total of 502,314 shares of Pfizer which is valued at $16,018,793. Pfizer makes up approx 2.07% of Community Trust Investment Co’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.